Johnson & Johnson (NYSE:JNJ) Shares Sold by Cheviot Value Management LLC

Cheviot Value Management LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 2.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 141,495 shares of the company’s stock after selling 3,330 shares during the period. Johnson & Johnson makes up 4.3% of Cheviot Value Management LLC’s holdings, making the stock its 4th biggest holding. Cheviot Value Management LLC’s holdings in Johnson & Johnson were worth $22,931,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of JNJ. Lynx Investment Advisory acquired a new position in shares of Johnson & Johnson during the 2nd quarter valued at $210,000. Sage Capital Advisors llc increased its stake in Johnson & Johnson by 0.7% in the second quarter. Sage Capital Advisors llc now owns 42,785 shares of the company’s stock valued at $6,254,000 after purchasing an additional 292 shares in the last quarter. Eastover Investment Advisors LLC raised its holdings in shares of Johnson & Johnson by 2.3% during the second quarter. Eastover Investment Advisors LLC now owns 38,982 shares of the company’s stock valued at $5,693,000 after purchasing an additional 878 shares during the period. Olistico Wealth LLC boosted its position in shares of Johnson & Johnson by 2.9% during the 2nd quarter. Olistico Wealth LLC now owns 3,584 shares of the company’s stock worth $524,000 after purchasing an additional 100 shares in the last quarter. Finally, Kingswood Wealth Advisors LLC grew its stake in shares of Johnson & Johnson by 32.4% in the 2nd quarter. Kingswood Wealth Advisors LLC now owns 29,557 shares of the company’s stock valued at $4,320,000 after buying an additional 7,227 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ opened at $155.10 on Monday. The firm has a 50-day moving average price of $159.15 and a 200-day moving average price of $156.46. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $373.42 billion, a price-to-earnings ratio of 22.43, a PEG ratio of 2.75 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.66 EPS. Equities analysts expect that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.20%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on JNJ. Citigroup increased their price target on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. Wells Fargo & Company increased their target price on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Royal Bank of Canada boosted their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Wolfe Research initiated coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Seven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $175.67.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.